Reports
Sale
Global Central Nervous System Treatment Market Size, Report: By Disease Type: Neurovascular Diseases, Neurodegenerative Diseases, Mental Health, Infectious Diseases, Others; By Drug Class: Immunomodulatory Drugs, Interferons, Decarboxylase Inhibitors, Others; By Drug Type: Regional Analysis; Competitive Landscape; 2024-2032
Global Central Nervous System Treatment Market Outlook
The global central nervous system treatment market is expected to grow at a CAGR of 8.1% during the period 2024-2032. The market is likely to be driven by development of new treatment systems, regulations seeking to support treatment systems for central nervous system disorders, and technological innovations. North America, Europe and Asia are expected to be key markets.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Global Market Likely to be Driven by Increasing Incidence of Neurological Disorders
The nervous system comprises central nervous system (CNS) (consisting of the brain and the spinal cord) and the peripheral nervous system (consisting of nerves, including the autonomic nervous system, outside of the brain and spinal cord, including those in the arms, legs, and trunk of the body). Together, the brain and the spinal cord act as the main "processing centre" for the entire nervous system, and control all the functions of the body.
Several different medical conditions could affect the nervous system, including degenerative diseases (including Alzheimer’s disease and Parkinson’s disease), blood vessel disorders in the brain (including arteriovenous malformations and cerebral aneurysms), tumours (benign and malignant), disorders of the pituitary gland, demyelinating diseases (such as multiple sclerosis), headaches (including migraines), epilepsy, head injuries like concussions and brain trauma, movement disorders (such as tremors and Parkinson’s disease), neuro-ophthalmologic diseases (vision problems as a result from damage to the optic nerve or its connections to the brain), peripheral nerve diseases (neuropathy), spine disorders, mental disorders (such as schizophrenia), infections (such as meningitis), stroke, etc.
Regulatory Frameworks Looking to Facilitate Development of Personalized Medicine Expected to Drive Market Growth
Central nervous system disorders signify a key area of unmet medical need. Personalized medicine (PM) is a novel concept that seeks to capitalize on known variability in patients, which causes differences in disease susceptibility and response to medication. The European regulatory network seeks to facilitate the development of PM methods for central nervous system disorders, including biomarkers (BMs), companion diagnostics, pharmacogenomics, and rare diseases; new methodologies and innovative clinical trial designs; and advanced treatments and therapies (e.g. gene therapies, somatic cell therapies, and tissue-engineered medicines). Such developments are expected to drive the global central nervous system treatment market. Increased focus on patient centricity and participation of patient groups has led to enhanced regulatory backing, including devoted scientific advice resources, new guidance documents, and multistakeholder platforms to meet challenges in PM development. Such initiatives led to some success (e.g., BM qualification), and there is hope that these would facilitate future approval of personalized central nervous system medicines.
Availability of Treatment Systems and Medical Practitioners Expected to Contribute to Market Growth
Neuroradiology (a branch of neuroscience medicine) seeks to diagnose and treat nervous system problems. Treatments include balloon angioplasty and stenting of carotid or vertebral artery; intra-arterial therapy for stroke; radiation oncology of the brain and spine; endovascular embolization and coiling to treat cerebral aneurysms; kyphoplasty and vertebroplasty to treat vertebral fractures; needle biopsies, spine and soft tissues; etc. Treatment may also include medicines [possibly administered by a drug pump (like those used for people with severe muscle spasms)], deep brain stimulation, spinal cord stimulation, rehabilitation/physical therapy after brain injury or stroke, spinal surgery, etc. Availability of treatment systems, along with that of health care providers, is expected to boost the global central nervous system treatment market. Health care providers from multiple specialties may be required to treat central nervous system related conditions. These may include neurologist, vascular surgeon, neurosurgeon, neuropsychologist, pain physician, psychiatrist, psychologist, radiologist, neuroscientist, nurse practitioners (NPs), physician assistants (PAs), nutritionists or dietitians, primary care doctors, physical therapists, occupational therapists, speech-language therapists, etc.
Market Segmentation
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
By type, the market is segmented into:
- Neurovascular Diseases (further broken down by type as given below)
- Hemorrhagic Stroke
- Ischemic Stroke
- Others
- Neurodegenerative Diseases (further broken down by type as given below)
- Alzheimer’s Disease
- Parkinson’s Disease
- Multiple Sclerosis
- Others
- Mental Health (further broken down by type as given below)
- Epilepsy
- Mood Disorders
- Anxiety Disorders
- Others
- Infectious Diseases (further broken down by type as given below)
- Meningitis
- Encephalitis
- Others
- Others
By drug class, the market is divided into:
- Immunomodulatory Drugs
- Interferons
- Decarboxylase Inhibitors
- Dopamine Agonists
- Antidepressants
- Analgesics
- Others
By drug type, the market is classified into:
- Biologics
- Non-Biologics
By region, the market is segmented into:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Key Industry Players in the Market
The report presents a detailed analysis of the following key players in the global central nervous system treatment market, looking into their capacity, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
- Teva Pharmaceutical Industries Ltd.
- Pfizer, Inc.
- F. Hoffmann-La Roche Ltd
- Otsuka Pharmaceutical Co., Ltd.
- Angelini S.p.a.
- Others
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Disease Type |
|
| Breakup by Drug Class |
|
| Breakup by Drug Type |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Central Nervous System Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Central Nervous System Treatment Historical Market (2018-2023)
8.3 Global Central Nervous System Treatment Market Forecast (2024-2032)
8.4 Global Central Nervous System Treatment Market by Disease Type
8.4.1 Neurovascular Diseases
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.1.3 Breakup by Type
8.4.1.3.1 Hemorrhagic Stroke
8.4.1.3.2 Ischemic Stroke
8.4.1.3.3 Others
8.4.2 Neurodegenerative Diseases
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.2.3 Breakup by Type
8.4.2.3.1 Alzheimer’s Disease
8.4.2.3.2 Parkinson’s Disease
8.4.2.3.3 Multiple Sclerosis
8.4.2.3.4 Others
8.4.3 Mental Health
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.4.3.3 Breakup by Type
8.4.3.3.1 Epilepsy
8.4.3.3.2 Mood Disorders
8.4.3.3.3 Anxiety Disorders
8.4.3.3.4 Others
8.4.4 Infectious Diseases
8.4.4.1 Historical Trend (2018-2023)
8.4.4.2 Forecast Trend (2024-2032)
8.4.4.3 Breakup by Type
8.4.4.3.1 Meningitis
8.4.4.3.2 Encephalitis
8.4.4.3.3 Others
8.4.5 Others
8.5 Global Central Nervous System Treatment Market by Drug Class
8.5.1 Immunomodulatory Drugs
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Interferons
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.5.3 Decarboxylase Inhibitors
8.5.3.1 Historical Trend (2018-2023)
8.5.3.2 Forecast Trend (2024-2032)
8.5.4 Dopamine Agonists
8.5.4.1 Historical Trend (2018-2023)
8.5.4.2 Forecast Trend (2024-2032)
8.5.5 Antidepressants
8.5.5.1 Historical Trend (2018-2023)
8.5.5.2 Forecast Trend (2024-2032)
8.5.6 Analgesics
8.5.6.1 Historical Trend (2018-2023)
8.5.6.2 Forecast Trend (2024-2032)
8.5.7 Others
8.6 Global Central Nervous System Treatment Market by Drug Type
8.6.1 Biologics
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Non-Biologics
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.7 Global Central Nervous System Treatment Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Central Nervous System Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Central Nervous System Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Central Nervous System Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Central Nervous System Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Central Nervous System Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Teva Pharmaceutical Industries Ltd.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Pfizer, Inc.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 F. Hoffmann-La Roche Ltd
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 Otsuka Pharmaceutical Co., Ltd.
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 Angelini S.p.a.
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Central Nervous System Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Central Nervous System Treatment Historical Market: Breakup by Disease Type (USD Million), 2018-2023
3. Global Central Nervous System Treatment Market Forecast: Breakup by Disease Type (USD Million), 2024-2032
4. Global Central Nervous System Treatment Historical Market: Breakup by Drug Class (USD Million), 2018-2023
5. Global Central Nervous System Treatment Market Forecast: Breakup by Drug Class (USD Million), 2024-2032
6. Global Central Nervous System Treatment Historical Market: Breakup by Drug Type (USD Million), 2018-2023
7. Global Central Nervous System Treatment Market Forecast: Breakup by Drug Type (USD Million), 2024-2032
8. Global Central Nervous System Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Central Nervous System Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Central Nervous System Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Central Nervous System Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Central Nervous System Treatment Market Structure
Key Questions Answered in the Report
The global central nervous system treatment market is projected to grow at a CAGR of 8.1% between 2024 and 2032.
The major drivers of the market include the increasing geriatric population, launch of new prospective products and pipeline drugs, favourable reimbursement policies, and improving healthcare infrastructure.
Increasing incidence of neurological disorders and regulations seeking to support treatment systems for central nervous system disorders are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
The different types of central nervous system treatment in the market are neurovascular diseases, neurodegenerative diseases, mental health, and infectious diseases, among others.
Based on drug class, the market is divided into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and analgesics, among others.
The various drug types in the market are biologics and non-biologics.
The major players in the industry are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., and Angelini S.p.a., among others.
Analyst Review
The global central nervous system treatment market was driven by the increasing incidence of neurological disorders in the historical period. Aided by the launch of new prospective products and pipeline drugs and favourable reimbursement policies, the market is expected to grow at a CAGR of 8.1% in the forecast period of 2024-2032.
EMR's meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. The different types of central nervous system treatment in the market are neurovascular diseases, neurodegenerative diseases, mental health, and infectious diseases, among others. Neurovascular diseases are further broken down into haemorrhagic stroke and ischemic stroke, among others while neurodegenerative diseases are sub-divided into Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, among others. Mental health is segmented into epilepsy, mood disorders, and anxiety disorders, among others, whereas infectious diseases are broken down into meningitis and encephalitis, among others. Based on drug class, the market is divided into immunomodulatory drugs, interferons, decarboxylase inhibitors, dopamine agonists, antidepressants, and analgesics, among others. The various drug types in the market are biologics and non-biologics. The major regional markets for central nervous system treatment market are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The major players in the industry are Teva Pharmaceutical Industries Ltd., Pfizer, Inc., F. Hoffmann-La Roche Ltd, Otsuka Pharmaceutical Co., Ltd., and Angelini S.p.a., among others.
EMR's research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable and help them remain ahead of their competition.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 2969
$2699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 5499
$4999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 6599
$5999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 7699
$6999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER